Publications by authors named "Brayan Merchan"

Claim this Profile
E
Enasidenib as treatment for AML with IDH2 mutation: multicenter real-life study of the early-access program in Spain.
Carlos Jiménez-Vicente, Paola Beneit, Isabel Cano-Ferri, Brayan Merchán, Montserrat Arnan

Ann Hematol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Juan Carlos Caballero, Julio Dávila, María López-Pavía, Esperanza Such, Teresa Bernal

Ther Adv Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphological central nervous system differentiation syndrome in acute promyelocytic leukemia relapse.
Juan Jose Rodriguez-Sevilla, Xavier Calvo, Sara Garcia, Brayan Merchan, Ana Ferrer

Int J Lab Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA.
Nieves Garcia-Gisbert, Sara Garcia-Ávila, Brayan Merchán, Marta Salido, Concepción Fernández-Rodríguez

Blood Adv· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
Alex Bataller, Ana Garrido, Francesca Guijarro, Guadalupe Oñate, Marina Diaz-Beyá, Brayan M Merchan

Blood Adv· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab in transfusion-dependent patients with low or intermediate-1 risk myelodysplastic syndromes.
Guillermo Garcia-Manero, Maria Diez-Campelo, Edo Vellenga, Meagan A Jacoby, Brayan Merchan

Am J Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Xavier Calvo, Nieves Garcia-Gisbert, Ivonne Parraga, Joan Gibert, Lourdes Florensa, Brayan Merchan

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia.
Georgina S Daher-Reyes, Brayan M Merchan, Karen W L Yee

Expert Opin Investig Drugs· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dichotomization of the new revised international prognostic scoring system for a better clinical stratification of patients with myelodysplastic syndromes.
Julia Montoro, Helena Pomares, Guillermo Villacampa, Brayan Merchán, Antonieta Molero

Leuk Lymphoma· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
Julia Montoro, Laura Gallur, Brayan Merchán, Antonieta Molero, Elisa Roldán

Ann Hematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.
David Valcárcel, Guillermo Sanz, Margarita Ortega, Benet Nomdedeu, Elisa Luño

Lancet Haematol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis